Aloe Vera in Chronic Periodontitis With Type 2 Diabetes Mellitus

Last updated: March 5, 2015
Sponsor: Government Dental College and Research Institute, Bangalore
Overall Status: Completed

Phase

2/3

Condition

Diabetes Mellitus, Type 2

Diabetes Prevention

Diabetes And Hypertension

Treatment

N/A

Clinical Study ID

NCT02386020
GDCRI/ACM/PG/PhD/10E/2013-14
  • Ages 25-45
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The present study is designed to investigate the effectiveness of AV gel local drug delivery as an adjunct to scaling and root planing (SRP) in the treatment of subjects with chronic periodontitis (CP) and type 2 diabetes mellitus (DM).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Well-controlled type 2 DM

  • Chronic periodontitis with moderate to deep pockets [probing depth (PD) ≥5mm andclinical attachment loss (CAL) ≥3mm]

  • No history of antibiotic or periodontal therapy in the preceding 6 months.

Exclusion

Exclusion Criteria:

  • Any known disease/condition or on any medication that can affect the periodontalstatus

  • Known or suspected allergy to herbal medications

  • Systemic antimicrobial therapy

  • Aggressive periodontitis

  • Smokers

  • Alcoholics

  • Immunocompromised patients

  • Pregnant or lactating females

Study Design

Total Participants: 60
Study Start date:
June 01, 2014
Estimated Completion Date:
December 31, 2014

Study Description

BACKGROUND: Advances in the field of alternative medicine have promoted widespread use of herbal agents, like Aloe vera (AV), for both medical and dental therapy. AV has anti-inflammatory, antioxidant, antimicrobial, hypoglycaemic, healing promoting and immune boosting properties. The present study is designed to investigate the effectiveness of AV gel local drug delivery as an adjunct to scaling and root planing (SRP) in the treatment of subjects with chronic periodontitis (CP) and type 2 diabetes mellitus (DM).

MATERIAL AND METHODS: A total of 60 subjects with probing depth (PD) ≥5mm and clinical attachment level (CAL) ≥3mm were randomly divided into two groups. Group 1 was treated with SRP + placebo gel local drug delivery (LDD) and Group 2 with SRP + AV gel LDD. Clinical parameters including full mouth plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD) and clinical attachment level (CAL) were recorded first at baseline and then at intervals of 3 months and 6 months.